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Abstract
Introduction: The RAD21 gene encodes a key component of the cohesin complex, which is essential for
chromosome segregation, and together with BRCA1 and BRCA2, for high-fidelity DNA repair by homologous
recombination. Although its expression correlates with early relapse and treatment resistance in sporadic breast
cancers, it is unclear whether familial breast cancers behave in a similar manner.
Methods: We performed an immunohistochemical analysis of RAD21 expression in a cohort of 94 familial breast
cancers (28 BRCA1, 27 BRCA2, and 39 BRCAX) and correlated these data with genotype and clinicopathologic
parameters, including survival. In these cancers, we also correlated RAD21 expression with genomic expression
profiling and gene copy-number changes and miRNAs predicted to target RAD21.
Results: No significant differences in nuclear RAD21 expression were observed between BRCA1 (12 (43%) of 28),
BRCA2 (12 (44%) of 27), and BRCAX cancers (12 (33%) of 39 (p = 0.598). No correlation was found between RAD21
expression and grade, size, or lymph node, ER, or HER2 status (all P > 0.05). As for sporadic breast cancers, RAD21
expression correlated with shorter survival in grade 3 (P = 0.009) and but not in grade 1 (P = 0.065) or 2 cancers (P
= 0.090). Expression of RAD21 correlated with poorer survival in patients treated with chemotherapy (P = 0.036)
but not with hormonal therapy (P = 0.881). RAD21 expression correlated with shorter survival in BRCA2 (P = 0.006)
and BRCAX (P = 0.008), but not BRCA1 cancers (P = 0.713). Changes in RAD21 mRNA were reflected by genomic
changes in DNA copy number (P < 0.001) and by RAD21 protein expression, as assessed with
immunohistochemistry (P = 0.047). High RAD21 expression was associated with genomic instability, as assessed by
the total number of base pairs affected by genomic change (P = 0.048). Of 15 miRNAs predicted to target RAD21,
mir-299-5p inversely correlated with RAD21 expression (P = 0.002).
Conclusions: Potential use of RAD21 as a predictive and prognostic marker in familial breast cancers is hence
feasible and may therefore take into account the patient’s BRCA1/2 mutation status.
Introduction
It is estimated that 5% to 10% of all breast cancers are
attributable to inherited mutations, of which the two
most important and highly penetrant are BRCA1 and
BRCA2 [1]. Studies have demonstrated key differences
in spontaneous BRCA-associated tumors [2,3]. BRCA1
cancers are more likely to show a basal phenotype, with
80% to 90% of BRCA1 cancers being negative for ER
and HER2 and positive for basal cytokeratins [4,5].
BRCA1 cancers also have characteristic gene-expression
and genomic profiles, and appear to be sensitive to
DNA damage by cisplatinum. Although reports suggest
that lobular carcinomas may be more frequent in
BRCA2 carriers, no specific molecular phenotype has
been described for BRCA2-associated tumors, which
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usually show a ductal, no-special-type morphology and
ER positivity [6].
RAD21 is a component of the multiprotein complex
cohesin, which is involved in maintaining alignment and
cohesion of replicated “sister” chromatids. RAD21,
together with SMC1, SMC3, and STAG1/2, forms a tri-
partite ring, which according to the “ring model,” pro-
motes sister chromatid cohesion (SCC) by encircling
sister chromatids [7]. SCC not only is vital for correct
chromosome segregation during mitosis and meiosis,
but also plays an important role in the repair of double-
stranded DNA breaks (DSBs). By promoting sister-chro-
matid alignment, cohesin allows BRCA1/2-mediated
homologous recombination to occur between sister
chromatids [8]. In addition to its role in maintaining sis-
ter-chromatid cohesion, evidence now suggests cohesins
are involved in promoting and inhibiting gene transcrip-
tion. In MCF-7 cell lines, genes cobound by cohesin and
ER are preferentially regulated by estrogen [9]. Cohesin
may also act as a negative regulator of gene expression,
by physically blocking enhancer/promoter interaction
[10].
Of the four proteins that compose the core cohesin
complex, RAD21 has emerged as a key marker of tumor
behavior. A meta-analysis of gene-expression data from
clinical cancer specimens showed that increased RAD21
expression was a feature of poorly differentiated breast,
ovarian, bladder, and lung cancers [11]. Gene-expression
profiling of 31 breast cancer patients with supraclavicu-
lar lymph node metastasis revealed RAD21 as one of six
genes that were differentially expressed between good-
and poor-outcome groups [12]. Our previous study on
sporadic breast cancers showed that RAD21 overexpres-
sion correlated with early relapse in high-grade breast
cancers regardless of intrinsic tumor subtype [13]. We,
and others, also showed that RAD21 knockdown confers
in vitro resistance to DNA-damaging chemotherapeutic
agents, which recapitulated the findings in our cohort of
sporadic breast cancers [13,14].
Although RAD21 overexpression correlates with early
relapse and treatment resistance in sporadic cancers, it
is unclear whether familial breast cancers behave in a
similar manner. This may be of particular relevance, as
RAD21, BRCA1, and BRCA2 are all involved in DNA
repair through homologous recombination; hence
RAD21 overexpression in the absence of either BRCA1
or -2 may not necessarily confer the same predictive
and prognostic implications as in sporadic cancers with
intact BRCA1/2. We therefore performed an immuno-
histochemical analysis of RAD21 expression in a cohort
of familial breast cancers. We also postulated that
enhanced RAD21 expression may be associated with
changes in both DNA copy number and reduced expres-
sion of microRNAs (miRNAs), and therefore correlated
RAD21 expression with genomic changes and miRNAs
predicted to target RAD21.
Materials and methods
Patients
Breast cancer specimens were collected from a pre-
viously characterized cohort of 139 female patients from
the kConFab family breast cancer registry (Table 1) [15].
Classification of BRCA1, BRCA2, and BRCAX status
was performed as described previously [15]. The flow of
patients according to the REMARK guidelines (Addi-
tional file 1 Table S1) [16]. Of the 139 cases, 18 cases
were excluded because of the lack of tissue available for
array construction, and a further 27 cases were excluded
because of the absence of tumor on the array stained
for RAD21. The final cohort was composed of 94 cases,
which included 28 BRCA1, 27 BRCA2, and 39 BRCAX
cases. This study has ethics committee approval (Peter
MacCallum Cancer Centre, 09/36). Consent to partici-
pate in the study and consent to publish were obtained
by kConFab in accordance with its family-enrollment
and data-collection guidelines [17]. Patients were fol-
lowed up for a median period of 64.0 months (range,
0.4 to 299.0 months). During this time, 38 patients
relapsed, and 33 died of breast cancer (deaths unrelated
to breast cancer were censored). Relapse-free survival
was defined as the time to first reappearance of tumor
at any site after definitive treatment, whereas breast can-
cer-specific survival was defined as time from primary
surgical excision to breast cancer-related death. All
patients with HER2-positive tumors were diagnosed
prior to 2000, and did not receive trastuzumab therapy.
Immunohistochemistry
Tumor-tissue microarrays (1-mm cores), with a twofold
redundancy, were prepared from archival formalin-fixed,
paraffin-embedded tissue blocks. RAD21 staining was
performed as previously described by using a rabbit
polyclonal anti-RAD21 antibody (1:200; Abcam, Cam-
bridge, UK) [13]. Nuclear RAD21 expression was
assessed for intensity (0, no staining; 1, weak; 2, moder-
ate; 3, strong) and the percentage of positive cells (0, 0;
1, < 10%; 2, 10% to 50%; 3, 51% to 80%; 4, > 80% posi-
tive cells). The scores for intensity and percentage were
added, and a cut-off of 6, the median, was used to
define two approximately equal sized groups of patients
(with low and high RAD21 expression) for subsequent
statistical analyses [13].
HER2 chromogenic in situ hybridization (CISH) and
immunoperoxidase staining for ERa, PgR, HER2, CK5/6,
and EGFR were performed for all tumors. By using stra-
tification of intrinsic phenotypes based on Nielsen et al.
[18], we placed tumors into luminal (ER positive, HER2
negative, cytokeratin (CK) 5/6 negative or positive),
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basal (HER2 and ER negative; CK5/6 positive), HER2
(HER2 positive, ER and CK5/6 negative or positive), and
null/negative (HER2, ER, and CK5/6 negative). For
HER2, EGFR, and CK5/6, the cut-offs were derived
from Neilsen et al. [18]. An Allred score of > 2/8 was
considered positive for ERa [19].
Gene-expression and copy-number analysis of RAD21
Gene-expression and copy-number variation (CNV) data
from a cohort of familial breast cancers were derived
from a previous study, by using the Illumina Human-6
BeadArray (Illumina, San Diego, CA, USA) and the
CNV370 SNP array (Illumina), respectively [20]. In this
study, the familial tumors were classified into one of the
breast tumor subtypes: basal-like, luminal A, luminal B,
HER2-positive, and normal-like. These data were used
to determine the expression of RAD21 in 75 (19
BRCA1, 30 BRCA2, 25 BRCAX, one unknown) familial
breast cancers. Of these 75 cases, 34 had matching CNV
data available (11 BRCA1, nine BRCA2, and 14
BRCAX), and 18 had matching protein-expression data
as assessed by immunohistochemistry (seven BRCA1,
eight BRCA2, three BRCAX). Copy number was deter-
mined by using SNP-CGH data for 34 tumors. All data
were imported and visualized in Beadstudio v3.2. The
logR ratio was used to perform frequency plots of geno-
mic gain or loss by using CGH explorer [21]. R was
used to perform SOMATICS [22] to identify regions
containing genomic aberrations. The copy number of
RAD21 in each tumor was inferred from the average
logR value of 22 single-nucleotide polymorphisms
(SNPs), which were within the RAD21 intron (n = 2) or
in sequences flanking the gene (n = 20). All these data
are available on GEO (Accession Number GSE19177).
microRNA and gene-expression data mining
Matching gene-expression and miRNA profiles of 215
sporadic breast cancer specimens were obtained by
mining a microarray dataset described by Buffa et al.
[23], in GEO (Accession number GSE22220), samples
BCmicroRNA 1 to 110). Normalized log2 signal intensi-
ties were obtained after background subtraction and
quantile normalization, as previously described by Buffa
et al. [23]. This signal intensity for RAD21 was used for
survival analysis, as outlined subsequently.
microRNA microarray
miRNA expression was assessed for 11 BRCA1 basal
breast cancers and 13 normal breast specimens via
microarrays. For each sample, 250 ng of total RNA was
labeled and hybridized on Human v2 MicroRNA
Expression BeadChips (Illumina). The BeadChips were
scanned with the Illumina iScan Reader [24]. Data were
imported into GenomeStudio (Illumina), from which
raw data with background subtraction were exported to
the PARTEK Genomics Suite (St. Louis, MO, USA) for
further analysis. Raw probe intensities were shifted, such
that the minimum probe intensity for each sample was
equal to 1. All values were transformed by taking logs
(base 2), followed by quantile normalization [25,26].











≤ 50 years 25 (89%) 15 (56%) 24 (61%) 64 (68%)
> 50 years 3 (11%) 12 (44%) 15 (39%) 30 (32%)
Tumor size
< 20 mm 20 (71%) 13 (52%) 16 (47%) 49 (56%)
> 20 mm 8 (29%) 12 (48%) 18 (53%) 38 (44%)
Unknown 0 2 5 7
Nodal status
Negative 26 (93%) 19 (70%) 25 (64%) 70 (74%)
Positive 2 (7%) 8 (30%) 14 (36%) 24 (26%)
Unknown 0 0 0 0
Grade
I 0 1 (4%) 2 (6%) 3 (4%)
II 2 (9%) 10 (44%) 8 (24%) 20 (25%)
III 21 (93%) 12 (52%) 23 (70%) 56 (71%)
Unknown 5 4 6 15
ERa
Negative 23 (85%) 5 (21%) 11 (32%) 39 (46%)
Positive 4 (15%) 19 (79%) 23 (68%) 46 (54%)
Unknown 1 3 5 9
PgR
Negative 23 (85%) 9 (38%) 16 (47%) 48 (56%)
Positive 4 (15%) 15 (62%) 18 (53%) 37 (44%)
Unknown 1 3 5 9
HER2 status
Negative 26 (100%) 22
(100%)
28 (85%) 76 (94%)
Positive 0 0 5 (15%) 5 (6%)
Unknown 2 5 6 13
Endocrine
therapy
Not given 22 (96%) 16 (76%) 21 (64%) 59 (77%)
Given 1 (4%) 5 (24%) 12 (36%) 18 (23%)
Unknown 5 6 6 17
Chemotherapy
Not given 8 (30%) 15 (60%) 13 (39%) 16 (42%)
Given 19 (70%) 10 (40%) 20 (61%) 49 (58%)
Unknown 1 2 6 9
n = 94.
Yan et al. Breast Cancer Research 2012, 14:R69
http://breast-cancer-research.com/content/14/2/R69
Page 3 of 11
Probe mapping for Illumina MicroRNA Expression v2
BeadChips was based on miRBase v.12.0 [27].
Statistical analysis
Correlations were evaluated by using the Mann-Whitney
U or c2 tests where appropriate. Kaplan-Meier survival
curves were calculated for breast cancer-specific death
and were compared with the log rank test. The Cox
proportional hazard regression model was used to iden-
tify independent prognostic factors for breast cancer-
specific survival. Analyses were performed with SPSS
16.0 software (SPSS Inc., 233 South Wacker Drive, Chi-
cago, IL, USA). A two-tailed P value test was used in all
analyses, and a P value of less than 0.05 was considered
statistically significant.
Results
RAD21 protein expression in familial breast cancers, their
relation with intrinsic subtypes and clinicopathologic
parameters
The median age of the cohort was 45.6 years. No differ-
ence was found in breast cancer-specific survival when
stratified by age, by using a cut-off of 40 years (P =
0.442). The tumors in our cohort showed either absent,
low, or high RAD21 expression (as defined earlier; Fig-
ure 1). With direct comparison of individual expression
scores or a median cut-off score, no significant differ-
ences in nuclear RAD21 expression were observed
between BRCA1 (12 (43%) of 28), BRCA2 (12 (44%) of
27), and BRCAX cancers (12 (33%) of 39) (P = 0.598)
(Additional file 2 Table S2a). Similarly, no differences in
Rad21 expression were seen within the intrinsic breast
cancer subtypes (luminal, 17 (42%) of 41; basal, 14
(44%) of 32; HER2, two (50%) of four; and null, one
(20%) of five; P = 0.768) (Additional file 2 Table S2b).
No correlation was seen between RAD21 expression and
tumor grade, size, lymph node status, or ER or HER2
status (all P > 0.05, Table 2).
RAD21 expression and survival in familial breast cancers
A significant correlation was noted between high-
RAD21 expression and shorter relapse-free survival (P
= 0.038) and breast cancer-specific survival (P = 0.001,
Figure 2A) across the entire familial cancer group.
Correlation with breast cancer-specific survival was
confirmed in a multivariate analysis (including ER,
HER2, tumor grade, size, lymph-node status), with
RAD21 as a continuous score out of seven (homolo-
gous recombination (HR) = 1.66; P = 0.003; 95% CI,
1.19 to 2.32; Table 3). Similar to our previous findings
in sporadic breast cancers [13], high RAD21 expression
correlated with poorer relapse-free survival (P = 0.008)
and breast cancer-specific survival for grade 3 familial
breast cancers (P = 0.009, Figure 2B) [13], but not for
grade 1 and 2 cancers (P = 0.065 and 0.090,
respectively).
Correlation of RAD21 expression with breast cancer-
specific survival was further assessed for BRCA1, BRCA2,
and BRCAX cancers. Interestingly, high RAD21 expres-
sion correlated with poorer survival in BRCA2 (P =
0.006) (Figure 2C) and BRCAX cancers (P = 0.008) (Fig-
ure 2D), but not in BRCA1 cancers (P = 0.71) (Figure
2E). When the intrinsic subtypes were individually ana-
lyzed, high RAD21 expression correlated with worse sur-
vival in luminal breast cancers (P = 0.010) (Figure 2F). A
similar divergence of the survival curves was observed in
basal cancers, although this was not statistically signifi-
cant (P = 0.075) (Figure 2G). Insufficient numbers of
HER2 and null-type cancers were available for survival
analyses to be performed (n = 2 and 3, respectively).
High RAD21 expression correlated with shorter survi-
val for patients treated with adjuvant chemotherapy (P =
0.036) (Figure 2H). Expression of RAD21 did not
Figure 1 Expression in invasive carcinoma. (A) High RAD21
nuclear expression in invasive carcinoma. (B) Absent RAD21
expression in invasive carcinoma.
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correlate with survival in patients receiving hormonal
therapy (p = 0.88).
Validation of RAD21 expression as a prognostic marker in
the cohort of sporadic cancers from Buffa et al
The correlation of RAD21 gene expression to 10-year
relapse-free survival was explored in a validation cohort
of 215 breast cancer patients, with tumors previously
characterized on the Illumina Human RefSeq-8 microar-
ray, by Buffa et al. [23]. Kaplan-Meier curves were
charted after stratifying the cohort into two groups, with
high RAD21 expression being defined at the 66th per-
centile (that is, top third of tumors). The same analysis
was repeated with the cut-off set at the 50th percentile.
High RAD21 expression correlated with poorer survival
at both cut-offs (P = 0.007 and P = 0.024, respectively;
Figure 3). At a cut-off at the 66th percentile, RAD21 was
an independent indicator of 10-year relapse-free survival
in a multivariate analysis including ER status, lymph
node status, grade, size, and age (HR = 1.62; P = 0.046;
95% CI, 1.08 to 2.61).
Gene expression correlates with relative copy number
and protein expression of RAD21 in familial breast
cancers
The cohort of familial tumors was previously analyzed
on the basis of gene-expression and copy-number analy-
sis [20]. No significant difference was found in RAD21
gene expression between BRCA1, BRCA2, and BRCAX
cancers (P = 0.170, Kruskal-Wallis test). Similarly, no
significant difference was noted in RAD21 copy number
among the BRCA subtypes (P = 0.141). Similar to our
findings in sporadic breast cancers, no difference was
seen in RAD21 copy number between basal-like and
luminal cancers (P = 0.749). The 34 tumors with both
gene-expression and copy-number data showed a signifi-
cant correlation between RAD21 expression and esti-
mated copy number (r = 0.619; P < 0.001) (Figure 4).
Five (15%) of the 34 tumors showed a copy-number
gain (copy number of 3). Of these five tumors with copy
number gain, there were four basal-like tumors and one
luminal tumor.
For 18 tumors, RAD21 gene expression was matched
with protein expression, as assessed by immunohisto-
chemistry. This showed a significant correlation between
RAD21 gene expression and RAD21 protein expression
(of seven) (r = 0.475; P = 0.047) (Figure 5).
RAD21 expression is linked with genomic instability in
familial breast cancers
Thirty-four tumors were analyzed for genomic change
by using SNP-CGH profiling, as previously described by
Waddell et al. [20]. SOMATICS [22] was used to iden-
tify copy-number change and copy-neutral loss of het-
erozygosity. The total number of chromosomal
aberrations and the total number of base pairs affected
by genomic change were compared between high
RAD21 (top third; n = 11) and low RAD21 (bottom
third; n = 11) expressing tumors, as assessed by gene-
expression analysis. Tumors with high RAD21 expres-
sion had a higher number of base pairs affected by
genomic change (mean = 1.92 × 109), compared with
tumors with low RAD21 expression (mean = 1.26 × 109;
P = 0.048; Figure 6). Although no significant difference
was found in the total number of chromosomal aberra-
tions between high and low RAD21-expressing tumors
(P = 0.660), the difference in the number of base pairs
affected by genomic change suggests that RAD21
expression is linked with a higher level of genomic
instability.
mir-299-5p is predicted to target RAD21 and inversely
correlates with RAD21 expression in sporadic breast
cancers
A search of potential miRNAs that may target RAD21
was performed on MicroCosm Targets, version 5 [28].
Table 2 Correlation of RAD21 expression with
clinicopathologic features (n = 94)
RAD21 negative RAD21 positive P value
Age
≤ 50 years 40 (70%) 24 (65%) 0.589
> 50 years 17 (30%) 13 (35%)
Tumor size
< 20 mm 29 (55%) 20 (59%) 0.706
> 20 mm 24 (45%) 14 (41%)
Nodal status
Negative 42 (74%) 28 (76%) 0.829
Positive 15 (26%) 9 (24%)
Grade
I 2 (5%) 1 (3%) 0.128
II 7 (16%) 13 (36%)
III 34 (79%) 22 (61%)
ERa
Negative 22 (44%) 17 (49%) 0.677
Positive 28 (56%) 18 (51%)
HER2 status
Negative 46 (96%) 30 (91%) 0.366
Positive 2 (4%) 3 (9%)
Relapse
Negative 44 (79%) 18 (51%) 0.007
Positive 12 (21%) 17 (49%)
BCSS
Negative 45 (80%) 19 (54%) 0.006
Positive 11 (20%) 16 (46%)
BCSS, Breast cancer-specific survival.
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Figure 2 Kaplan-Meier curves, breast cancer-specific overall survival stratified by Rad21 expression. (A) All familial cancers (P = 0.001).
(B) Grade 3 familial cancers (P = 0.009). (C) BRCA2 cancers (P = 0.006). (D) BRCAX cancers (P = 0.008). (E) BRCA1 cancers (P = 0.071). (F) Familial
luminal cancers (P = 0.010). (G) Familial basal cancers (P = 0.075). (H) Familial cancers treated with adjuvant chemotherapy (P = 0.036).
Yan et al. Breast Cancer Research 2012, 14:R69
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The correlation between RAD21 gene expression and
the expression of 15 miRNAs predicted to target RAD21
was interrogated by mining matching gene-expression
and miRNA-array data from the cohort of Buffa et al.
(108 tumors from miRNA arrays 1 to 110) [23]. Of the
15 miRNAs examined, mir-299-5p inversely correlated
with RAD21 expression (Pearson r = -0.294; P = 0.002).
Discussion
Although RAD21 expression is associated with a poor
prognosis and treatment resistance in sporadic breast
cancers, the role of RAD21 in familial breast cancers is
unclear, as RAD21 expression in the absence of either
functional BRCA1 or 2 may not necessarily confer the
same predictive and prognostic implications as in spora-
dic cancers with intact BRCA1/2. We therefore per-
formed the first analysis of RAD21 in a cohort of fully
characterized familial breast cancers and investigated
potential mechanisms that may mediate RAD21 levels,
including DNA copy number and reduced expression of
targeting microRNA.
Our findings in a cohort of familial breast cancers
recapitulated our previous findings in sporadic breast
cancers, with enhanced expression of RAD21 occurring
in a subset of tumors regardless of grade, size, or intrin-
sic subtype [13]. Similarly, RAD21 expression conferred
a poor prognosis in grade 3, but not in grade 1 or 2
cancers. The previously demonstrated correlation of
RAD21 with survival was also confirmed in the cohort
of Buffa et al. of sporadic cancers assessed with gene-
expression arrays and in our cohort of familial breast
cancers.
We found that RAD21 expression does not correlate
with BRCA status. However, its expression associates
with a poor prognosis in BRCA2 and BRCAX cancers.
This finding is consistent with our previous findings in
sporadic cancers [13]. Interestingly, RAD21 was not
associated with a poor prognosis in BRCA1 cancers.
How RAD21 expression influences the poor prognosis
in BRCA2 and BRCAX but not in BRCA1 patients
remains to be determined. This finding is likely to be
Table 3 Cox regression model: factors influencing breast







RAD21 (score out of
7)
0.003 1.66 1.19-2.32
ER 0.088 0.33 0.09-1.18
HER2 0.088 2.24 0.51-9.97
Grade 0.030 5.66 1.18-27.22
Size 0.691 0.99 0.97-1.02
Lymph-node status 0.003 6.05 1.82-20.15
Figure 3 The 10-year relapse-free survival of 215 patients from Buffa et al. [23], stratified by RAD21 gene expression. (A) Cut-off at 66th
percentile (that is, top third), and (B) cut-off at 50th percentile (that is, top half).
Figure 4 Correlation between RAD21 gene copy-number
changes as assessed by the average logR array value of 24
single-nucleotide polymorphisms (SNPs). These were located in
RAD21 or within the flanking region of the gene and normalized
expression of RAD21 in 34 breast cancers.
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explained by the final roles of RAD21 and BRCA1/2 in
homologous recombination (HR). Like BRCA1 and
BRCA2, cohesins are important regulators of genomic
stability. Cohesins facilitate error-free repair of double-
stranded breaks (DSBs) in DNA by HR, possibly by pro-
moting the alignment and cohesion of sister chromatids
[8]. Defects in HR result in DSB repair through the
alternative, error-prone, nonhomologous end-joining
and single strand-annealing pathways; this may lead to
deletions, translocations, and chromosomal instability
[29]. HR is particularly important in the repair of DNA
damage caused by chemotherapeutic agents and radio-
therapy. Although both BRCA1 and BRCA2 participate
in HR, evidence from genetic studies suggests that
BRCA1 functions upstream of BRCA2 [30]. Hence, in
the setting of BRCA1 cancers in which DSB repair has
already been compromised by deleterious BRCA1 muta-
tions, overexpression of RAD21 may have no effect on
tumor behavior. Furthermore, removal of the cohesin
complex after DNA repair requires proteolytic cleavage
of RAD21 by caspase 3 [31]. Activation and transloca-
tion of caspase 3 into the nucleus requires functioning
wild-type BRCA1 and is inhibited by mutated BRCA1
[32]. Failure to cleave RAD21 due to BRCA1-dependent
caspase 3 inhibition may explain loss of HR repair in
BRCA1 but not in BRCA2 cancers.
Another possible explanation relates to the emerging
role of cohesin as a key regulator of gene transcriptions
[33,34]. RAD21 is implicated in mediating estrogen-
regulated transcription through ERa in MCF7 breast
cancer cells [9]. Hence RAD21 expression may influence
a subset of gene expression through interplay with ERa,
and thereby contribute to the poor prognosis in BRCA2
and BRCX patients. This notion is consistent with ER
status in our cohort, in which 85% of BRCA1 tumors
are ERa negative. Although RAD21 may be implicated
in ER-regulated gene expression, functional genomic
screens performed on estrogen-dependent cell lines have
so far yielded conflicting results regarding the role of
RAD21 in tamoxifen resistance. Silencing of RAD21 via
sh-RNA suggests that RAD21 expression is associated
with sensitivity to tamoxifen [35], whereas transduction
by retroviral cDNA suggests that RAD21 expression is
associated with resistance [36]. Neither of these findings
appears to be reflected by our clinical cohorts, as Rad21
expression did not correlate with survival in either
sporadic (P = 0.231) or familial (P = 0.881) breast can-
cers treated with hormone therapy.
Our previous study demonstrated that RAD21 expres-
sion is associated with chemotherapy resistance in cell
lines and in a cohort of sporadic cancers [13]. Similarly,
in our cohort of familial cancers receiving adjuvant che-
motherapy, RAD21 expression correlated with a poorer
prognosis. This is despite our finding that RAD21 does
not correlate with survival in BRCA1 cancers and the
higher use of chemotherapy in BRCA1 cancers. This
further supports our argument that BRCA1 cancers
behave differently from other cancers in response to
RAD21 overexpression.
Although the function of RAD21 has been extensively
investigated in the literature, relatively little is known
regarding the regulation of its expression. In keeping
with our previous findings in sporadic breast cancers
[13], RAD21 gene expression correlated with copy num-
ber in our cohort of familial breast cancers. This is
further supported by the positive correlation between
RAD21 gene expression and protein expression, as
assessed by immunohistochemistry in matched tumor
Figure 5 Correlation of RAD21 gene expression with RAD21
immunohistochemistry (score out of 7). r = 0.475; P = 0.047.
Figure 6 Comparison of the total number of base pairs
affected by genomic change between tumors with low (n =
11) and high (n = 11) RAD21 gene expression, P = 0.048.
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samples. Increased RAD21 expression is associated with
increased numbers of base pairs being affected by geno-
mic change, which suggests that increased expression is
linked to genomic instability. The effect of genomic
changes on RAD21 expression appears to be indepen-
dent of BRCA status and intrinsic tumor subtype.
RAD21 upregulation may be an early event that occurs
before tumor invasion. This is supported by the pre-
sence of increased RAD21 expression in 46% of the
DCIS cases we previously examined [13]. In addition,
interrogation of the cohort of Schuetz et al. [37] showed
no difference in RAD21 expression between 14 micro-
dissected matching invasive and in situ ductal carcinoma
samples (P = 0.154).
In addition to genomic changes, we postulated that
other mechanisms are likely to control RAD21 expres-
sion, such as through targeting microRNAs. Of the 15
miRNAs predicted to target RAD21, mir-299-5p expres-
sion significantly inversely correlated with RAD21
expression. Reduced circulating mir-299-5p was pre-
viously demonstrated in the serum of breast cancer
patients [38], compared with normal controls. Silencing
of mir-299-5p has also been implicated in the pathogen-
esis of oral squamous cell carcinomas [39]. Limited data
derived from breast cancer cell lines showed that mir-
299-5p knockdown is associated with upregulation of
osteopontin [40], a glycoprotein involved in invasion,
metastasis, and resistance to radiotherapy and che-
motherapeutic agents [41,42]. Aberrant regulation of
RAD21 by mir-299-5p is also supported by a compari-
son of 11 BRCA1 basal and 13 normal breast samples,
in which a sevenfold reduction in mir-299-5p was
observed between BRCA1 cancers and normal breast tis-
sue (P = 0.0002; Figure 7). Nevertheless, although mir-
299-5p is clearly reduced in breast cancer, this appears
appear to play a relatively minor role in regulating
RAD21 expression (r2 = 0.0864; P = 0.002) compared
with genomic changes in copy number (r2 = 0.286; P <
0.001).
In summary, our findings show that RAD21 expres-
sion is associated with a poorer prognosis in BRCA2
and BRCAX, but not in BRCA1 cancers. Because
increased RAD21 expression may confer resistance to
DNA-damaging agents, alternative treatment strategies
may be useful in RAD21-positive BRCA2 and BRCAX
cancers. This may include dosage intensification and the
use of chemotherapeutic agents with alternative modes
of action. The efficacy of poly-ADP ribose polymerase
(PARP)-inhibitor therapy is dependent on defective HR
repair [43,44]. In view of the role of RAD21 in increas-
ing HR activity [33], tumor RAD21 status may be parti-
cularly relevant in patients being considered for PARP-
inhibitor therapy.
Conclusions
RAD21 expression in familial cancers is reflected by
expression changes in copy-number expression. It is
also inversely correlated with mir-299-5p, the expression
of which is suppressed in breast cancers. Similar to our
earlier findings in sporadic breast cancers, increased
RAD21 expression in BRCA2 and BRCAX cancers con-
fers a poor prognosis and resistance to DNA-damaging
chemotherapeutic agents. This association does not
apply to BRCA1 cancers, in which repair by HR between
sister chromatids may be compromised by BRCA1 defi-
ciency. RAD21 is thus a potential BRCA1/2 mutation
status-dependent predictive and prognostic marker in
familial breast cancers.
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